Dupilumab provides sustained effectiveness on patient-reported outcomes and favorable safety in patients with moderate-to-severe atopic dermatitis: Up to 5-year results from the daily practice BioDay registry.
J Am Acad Dermatol
; 91(2): 300-311, 2024 Aug.
Article
in En
| MEDLINE
| ID: mdl-38653344
ABSTRACT
BACKGROUND:
Long-term daily practice data on patient-reported benefits of dupilumab for atopic dermatitis (AD) remains limited.OBJECTIVE:
To evaluate patient-reported outcome measures (PROMs) and the safety of dupilumab in patients with moderate-to-severe AD over a follow-up period of up to 5 years.METHODS:
Data were extracted from the prospective, multicenter BioDay registry (October 2017-2022) of patients with moderate-to-severe AD treated with dupilumab in daily practice.RESULTS:
In total 1223 patients, 1108 adults and 115 pediatric patients were included. After ≥1 year of treatment, mean Patient-Oriented Eczema Measure (POEM), Dermatology Life Quality Index (DLQI), Numeric rating scale (NRS)-pruritus ranged between 7.8 and 8.7, 3.5 and 4.2, and 2.9 and 3.1 in adults, respectively, whilst these patient-reported outcome measures (PROMs) ranged between 8.9 and 10.9, 4.4 and 6.4, and 3.0 and 3.7 in pediatric patients, respectively. At follow-up, overall work impairment decreased from 40.1% to 16.3% to 13.3% in adults. Furthermore, class I obesity and itch-dominant patients generally had less favorable treatment response. Of all patients, 66.8% reported ≥1 adverse event, with conjunctivitis being the most common (33.7%).LIMITATIONS:
The overall percentage of missing values for selected PROMs was 26% in adults and 46% in pediatric patients.CONCLUSION:
In addition to favorable safety, dupilumab has demonstrated sustained effectiveness across various PROMs, underscoring the treatment benefits from patients' perspectives.Key words
Full text:
1
Database:
MEDLINE
Main subject:
Severity of Illness Index
/
Registries
/
Dermatitis, Atopic
/
Antibodies, Monoclonal, Humanized
/
Patient Reported Outcome Measures
Limits:
Adolescent
/
Adult
/
Aged
/
Child
/
Child, preschool
/
Female
/
Humans
/
Male
/
Middle aged
Language:
En
Year:
2024
Type:
Article